Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (1): 111-118    DOI: 10.13523/j.cb.20170116
    
The Analysis of Vaccine Market
LI Min
Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China
Download: HTML   PDF(667KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Vaccine is the most effective weapon for the prevention of the disease, which is the public medical product that everyone can't be separated from and has made great contributions to the health of all mankind. There are about 68 kinds of vaccines in the global market at present and can prevent 34 kinds of diseases. Global vaccine markets maintain steady growth. Vaccine sales increased year by year and the market sales were 29.6 billion dollars in 2015. The top 5 companies, Pfizer, Merck, Sanofi, GSK, Novartis, occupied more than 85% of the market share. A variety of vaccine products had good sales performance. China vaccine markets also grow consistently with a market value of 18.37 billion in 2015. The issued amount of vaccine was 704 million bottles in 2015. The types of vaccine productions are increased and the ability of vaccine research and development is gradually strengthened. The vaccine markets in emerging countries are gradually developing and India performs excellently. The internationalization of Chinese vaccine industry is not as good as India, but it also made a lot of progress. Chinese vaccine industry entering the international market has become an irreversible trend in the future.



Key wordsVaccine      Emerging countries      Vaccine market     
Received: 07 July 2016      Published: 25 January 2017
ZTFLH:  Q819  
Cite this article:

LI Min. The Analysis of Vaccine Market. China Biotechnology, 2017, 37(1): 111-118.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170116     OR     https://manu60.magtech.com.cn/biotech/Y2017/V37/I1/111

[1] 高云华, 吴曙霞, 刁天喜. 预防疫苗产业市场的现状与发展趋势. 中国新药杂志, 2008, 17(20):1736-1738. Gao Y H, Wu SH X, Diao T X. The current status and trends of the preventive vaccine market. Chinese Journal of New Drugs, 2008, 17(20):1736-1738.
[2] 王福清, 易静薇, 赵晓嬿, 等. 我国疫苗产业发展现状与展望. 中国生化药物杂志, 2009, 30(4):287-290. Wang F Q, Yi J W, Zhao X Y, et al. The development status and perspective of vaccine industry in China. Chinese Journal of Biochemical Pharmaceutics, 2009, 30(4):287-290.
[3] 丁辉. 生物制药前景广阔, 细分行业各有千秋. 江苏科技信息, 2011, (5):40-42. Ding H. Good prospects for biopharmaceutical industry with merits in each segments. Jiangsu Science and Technology Information, 2011, (5):40-42.
[4] 王永庆. 加快疫苗产业自主发展,确保国家生物安全. 经济界, 2015, (3):6-7. Wang Y Q. Accelerating the development of the vaccine industry, ensuring the safety of national biological. Economic Affairs, 2015, (3):6-7.
[5] Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature, 2011, 473(7348):463-469.
[6] 于盟. 全球疫苗市场综述. 精细与专用化学品, 2015, 23(11):10-12. Yu M. Overview on the global vaccine market. Fine and Specialty Chemicals, 2015, 23(11):10-12.
[7] Kennedy R B, Ovsyannikova I G, Lambert N D, et al. The personal touch:strategies toward personalized vaccines and predicting immune responses to them. Expert Rev Vaccines, 2014, 13(5):657-669.
[8] Delany I, Rappuoli R, Seib K L. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med, 2013, 3(5):a012476.
[9] 于盟.中印疫苗产业国际化对比. 医药经济报, 2015-05-27(003版). Yu M. International comparison of vaccine industry in China and India. Medicine Economic Report, 2015-95-27(003).
[10] 阿丽塔, 刘晓婷, 孙灵芝. 全球疫苗产业现状与发展趋势. 2011, 20(22):16-18. A L T, Liu X T, Sun L Z. Current status and development trend of global vaccine industry. China Pharmaceuticals, 2011, 20(22):16-18.

[1] XIAO Yun-xi,ZHANG Jun-he,YANG Wen-wen,CHENG Hong-wei. Research Progress of Human Diploid Cells for Vaccine Production[J]. China Biotechnology, 2021, 41(11): 74-81.
[2] ZHU Xiao-jing,WANG Rui,ZHANG Xin-xin,JIN Jia-xin,LU Wen-long,DING Da-shun,HUO Cui-mei,LI Qing-mei,SUN Ai-jun,ZHUANG Guo-qing. Construction of MDV Recombinant Vaccine Strain Integrated F Gene Using Bacterial Artificial Chromosome Technique[J]. China Biotechnology, 2021, 41(10): 33-41.
[3] CHENG Xu,YANG Yu-qing,WU Sai-nan,HOU Qin-long,LI Yong-mei,HAN Hui-ming. Construction of DNA Vaccines of Staphylococcus aureus SarA, IcaA and Their Fusion Genes and Preliminary Study in Mouse Immune Response[J]. China Biotechnology, 2020, 40(7): 41-50.
[4] LIU Zhen-zhen,TIAN Da-yong. Development of Sucrose Density Gradient Centrifugation Purification Process for Rabies Vaccine[J]. China Biotechnology, 2020, 40(4): 25-33.
[5] QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.
[6] XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.
[7] JING Hui-yuan,DUAN Er-zhen,DONG Wang. In Vitro Transcribed Self-amplifying mRNA Vaccines[J]. China Biotechnology, 2020, 40(12): 25-30.
[8] LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.
[9] FENG Xue-jiao,HOU Hai-long,YU Qiong,WANG Jun-shu. Market Analysis and Countermeasures of Cervical Cancer Vaccine in China[J]. China Biotechnology, 2020, 40(11): 96-101.
[10] Yan GAO,Jing-jing DU,Bin WANG,Qi LIU,Zhi-qiang SHEN. Study on β-Propiolactone in Inactivation Process of Rabies Vaccine by Gas Chromatography[J]. China Biotechnology, 2019, 39(6): 25-31.
[11] Lin YANG,Zhe-yan FU,Zheng-bing LV,Jian-hong SHU. Classification and Mechanism of Immune Adjuvant[J]. China Biotechnology, 2019, 39(5): 114-119.
[12] Jia-yue XU,Zi-qian LI,Ge ZHANG. Advanced in Research Dengue Virus 3'UTRΔ30 Series Vaccines[J]. China Biotechnology, 2019, 39(3): 97-104.
[13] Fu-lan GAO,Jia-long QI,Cong-yan SHU,Hang-hang XIE,Wei-wei HUANG,Cun-bao LIU,Xu YANG,Wen-jia SUN,Hong-mei BAI,Yan-bing MA. Efficient Secretory Expression of Optimized Mouse Interleukin-33 Gene in Mammalian Cells[J]. China Biotechnology, 2019, 39(3): 46-55.
[14] Xi-wen JIANG,Zi-wei DONG,Yue LIU,Xiao-ya ZHU. Reserch Progress on Biomarkers and Precision Medicine[J]. China Biotechnology, 2019, 39(2): 74-81.
[15] SUN Si,QIU Yu-lan,YAN Ju-rong,YANG Jing,WU Guang-ying,WANG Lin,XU Wen-chun. Recombinant Plasmid pcDNA3-dnaJ Prime/DnaJ Protein Boost Immunization Induce Th1/Th17 Immune Responses and Protect Mice Against Pneumococcal Infection[J]. China Biotechnology, 2019, 39(12): 9-17.